New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Vortioxetine is a novel antidepressant with effects on multiple 5-HT receptors and on the serotonin transporter. This paper reviews preclinical and clinical evidence regarding its mechanism of action, its tolerability, and its efficacy in treating major depression. Clinical studies indicate that vortioxetine is effective in the treatment of major depression, though there is no suggestion of superiority over active comparators. There may be a clinically meaningful advantage in terms of tolerability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bang-Andersen, B., Ruhland, T., Jørgensen, M., Smith, G., Frederiksen, K., Jensen, K. G., Zhong, H., Nielsen, S. M., Hogg, S., Mørk, A., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101459g · Cited by 606 · cited 1×
“It has been shown in recombinant cell lines to combine 5-HT 3 and 5-HT 7 receptor antagonism, 5-HT 1B receptor partial agonism, 5-HT 1A receptor agonism, and serotonin transporter inhibition.(4)”
Katona, C., Hansen, T., & Olsen, C. K. (2012) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283542457 · Cited by 445 · cited 2×
“It is perhaps noteworthy that in three of the above studies, 18,20,23 although formal statistical comparison between active drugs was not reported, there was a trend for the SNRI active comparator to be associated with numerically superior outcomes to vortioxetine.”
InfluentialSelf-citationMørk, A., Pehrson, A., Brennum, L. T., Nielsen, S. M., Zhong, H., Lassen, A. B., Miller, S., Westrich, L., Boyle, N. J., Sánchez, C., et al. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.189068 · Cited by 271
Alvarez, E., Perez, V., Dragheim, M., Loft, H., & Artigas, F. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001027 · Cited by 225 · cited 2×
“It is perhaps noteworthy that in three of the above studies, 18,20,23 although formal statistical comparison between active drugs was not reported, there was a trend for the SNRI active comparator to be associated with numerically superior outcomes to vortioxetine.”
Pehrson, A. L., Cremers, T., Bétry, C., van der Hart, M. G. C., Jørgensen, L., Madsen, M., Haddjeri, N., Ebert, B., & Sanchez, C. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.04.006 · Cited by 155
Henigsberg, N., Mahableshwarkar, A. R., Jacobsen, P., Chen, Y., & Thase, M. E. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07470 · Cited by 150
du Jardin, K. G., Jensen, J. B., Sanchez, C., & Pehrson, A. L. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.07.001 · Cited by 133
Jain, R., Mahableshwarkar, A. R., Jacobsen, P. L., Chen, Y., & Thase, M. E. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000727 · Cited by 132
Boulenger, J.-P., Loft, H., & Florea, I. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112441866 · Cited by 127
The Clinical Pharmacokinetics of Lu AA 21004 and its Major Metabolite in Healthy Young Volunteers
Areberg, J., Søgaard, B., & Højer, A. (2012) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2012.00886.x · Cited by 69 · cited 1×
“9,10 Areberg et al 11 carried out an extensive human pharmacokinetic study.”
Cited by
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“Vortioxetine is a new generation antidepressant, which appears to have comparable antidepressant efficacy to SRRIs, SNRIs and agomelatine, but a comparison of efficacy with TCAs and MAOIs is not yet available (Citrome, 2015; Katona and Katona, 2014; Sanchez et al., 2015; Schatzberg et al., 2014).”
BackgroundThe molecular pathophysiology of depression and the new therapeutics
Tian, H., Hu, Z., Xu, J., & Wang, C. (2022) · MedComm · doi:10.1002/mco2.156 · Cited by 122
Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant
Sowa-Kućma, M., Pańczyszyn-Trzewik, P., Misztak, P., Jaeschke, R. R., Sendek, K., Styczeń, K., Datka, W., & Koperny, M. (2017) · Pharmacological Reports · doi:10.1016/j.pharep.2017.01.030 · Cited by 86
Metadata
- Authors
- Katona, C., & Katona, C.
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2014-02
- Volume
- 10
- Pages
- 349
- ISSN
- 1176-6328 (ISSN-L)
- OpenAlex
- W2050728144
- Cited by
- 54
- References
- 10
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. https://app.cochat.ai/papers/10.2147/ndt.s39544
- The paper
- Katona, C., & Katona, C. (2014). New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. Neuropsychiatric Disease and Treatment. https://doi.org/10.2147/ndt.s39544
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.